1. Home
  2. GIFT vs RNTX Comparison

GIFT vs RNTX Comparison

Compare GIFT & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo RDE Inc.

GIFT

RDE Inc.

N/A

Current Price

$1.11

Market Cap

33.1M

ML Signal

N/A

RNTX

Rein Therapeutics Inc.

N/A

Current Price

$1.21

Market Cap

35.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GIFT
RNTX
Founded
1999
2001
Country
United States
United States
Employees
N/A
N/A
Industry
Catalog/Specialty Distribution
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
33.1M
35.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
GIFT
RNTX
Price
$1.11
$1.21
Analyst Decision
Strong Buy
Buy
Analyst Count
1
2
Target Price
$4.00
$10.00
AVG Volume (30 Days)
61.0K
208.6K
Earning Date
11-10-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$86,142,442.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$7.20
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.82
$1.02
52 Week High
$2.38
$3.50

Technical Indicators

Market Signals
Indicator
GIFT
RNTX
Relative Strength Index (RSI) 48.84 51.08
Support Level $1.03 $1.12
Resistance Level $1.15 $1.36
Average True Range (ATR) 0.05 0.09
MACD 0.00 0.01
Stochastic Oscillator 41.67 63.25

Price Performance

Historical Comparison
GIFT
RNTX

About GIFT RDE Inc.

Giftify Inc through its wholly-owned subsidiary, has been in the business of connecting digital consumers, businesses and communities with dining and merchant deal options throughout the United States. The company connects digital consumers, businesses, and communities offering dining and merchant deal options nationwide restaurants, and retailers to customers. The Company buys merchant gift cards from the general public and distributors at a discount and then resells them at a markup.

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.

Share on Social Networks: